In October, the biopharma industry secured $11.6 billion in financings, marking the highest monthly amount since June 2021 when value totaled $12.3 billion. Biopharma financings have averaged $6.1 billion per month so far in 2023, an increase from the $5.07 billion monthly average for all of 2022. Read More
The largest genetic analysis of abdominal aortic aneurysm (AAA) carried out to date has identified almost 100 new risk variants linked to the disorder. The study also highlighted a possible therapeutic target for this pathology that, at the moment, has no treatment. AAA affects 4% of people over 65 years of age in the U.S. and causes 41,000 deaths per year. The incidence is three to four times higher in men than in women. Read More
The U.S. Department of Justice (DOJ) has a unique role in enforcement of medical product communication even though the department shares oversight of medical product promotions with the FDA and the Federal Trade Commission (FTC). Read More
The latest firm to brave the rough IPO market, Lexeo Therapeutics Inc. made its Nasdaq debut after pricing about 9.1 million shares at $11 per share, raising proceeds of $100 million to advance its early clinical work on gene therapies for cardiovascular and neurological diseases. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Chipscreen, Ocuphire, Outlook, Phathom, Pierre Fabre, Prokarium, Reset, Scilex, Sumitomo, Supernus, Verona. Read More
